{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:32:33Z","timestamp":1774686753383,"version":"3.50.1"},"reference-count":46,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,3,1]]},"abstract":"<jats:p>Severe insulin resistance is a key abnormality in obese women with polycystic ovary syndrome (PCOS). The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment. Fifty-two women with PCOS were randomly allocated to receive either pioglitazone (30 mg\/d, n = 25) or metformin (850 mg three times daily, n = 27) and were assessed before and after 6 months. Body weight, body mass index, and waist to hip ratio increased significantly (P \u2264 0.05) after pioglitazone treatment but not after metformin treatment. Fasting serum insulin concentration (P &amp;lt; 0.001 for both drugs) and the area under the insulin curve during a 2-h oral glucose tolerance test decreased after pioglitazone (P &amp;lt; 0.002) or metformin (P &amp;lt; 0.05) treatment. IR (homeostasis model of assessment-IR index) decreased and insulin sensitivity (elevation of the quantitative insulin sensitivity check index and the fasting glucose to insulin ratio) increased (P \u2264 0.008) after treatment with either drug. Hirsutism (P &amp;lt; 0.05) and serum concentrations of free testosterone (P &amp;lt; 0.02) and androstenedione (P &amp;lt; 0.01) declined to a similar extent after treatment with the drugs. Treatment with pioglitazone or metformin was associated with the occurrence of pregnancy (n = 5 and n = 3, respectively). These results suggest that pioglitazone is as effective as metformin in improving insulin sensitivity and hyperandrogenism, despite an increase in body weight, body mass index, and the waist to hip ratio associated with pioglitazone.<\/jats:p>","DOI":"10.1210\/jc.2004-1965","type":"journal-article","created":{"date-parts":[[2005,3,9]],"date-time":"2005-03-09T23:59:24Z","timestamp":1110412764000},"page":"1360-1365","source":"Crossref","is-referenced-by-count":165,"title":["Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome"],"prefix":"10.1210","volume":"90","author":[{"given":"C.","family":"Ortega-Gonza\u0301lez","sequence":"first","affiliation":[{"name":"Department of Endocrinology (C.O.-G., S.L., L.H., G.C., A.P.),Me\u0301xico City, Me\u0301xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Luna","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (C.O.-G., S.L., L.H., G.C., A.P.),Me\u0301xico City, Me\u0301xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Herna\u0301ndez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (C.O.-G., S.L., L.H., G.C., A.P.),Me\u0301xico City, Me\u0301xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Crespo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (C.O.-G., S.L., L.H., G.C., A.P.),Me\u0301xico City, Me\u0301xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Aguayo","sequence":"additional","affiliation":[{"name":"Department of Sterility (P.A.), Me\u0301xico City, Me\u0301xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Arteaga-Troncoso","sequence":"additional","affiliation":[{"name":"Direction of Investigation (G.A.-T.), Instituto Nacional de Perinatologi\u0301a, 11000 Me\u0301xico City, Me\u0301xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Parra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (C.O.-G., S.L., L.H., G.C., A.P.),Me\u0301xico City, Me\u0301xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071615453605400_R1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0015-0282(03)00733-7","article-title":"What are the key features of importance in polycystic ovary syndrome?","volume":"80","author":"Lobo","year":"2003","journal-title":"Fertil Steril"},{"key":"2020071615453605400_R2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"2020071615453605400_R3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1210\/jcem-50-1-113","article-title":"Correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease.","volume":"50","author":"Burghen","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R4","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"key":"2020071615453605400_R5","first-page":"697","article-title":"Current perspectives in polycystic ovary syndrome.","volume":"68","author":"Richardson","year":"2003","journal-title":"Am Fam Physician"},{"key":"2020071615453605400_R6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00060793-200208000-00003","article-title":"Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome.","volume":"9","author":"Baillargeon","year":"2002","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"2020071615453605400_R7","first-page":"2001","article-title":"Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system.","volume":"83","author":"Nestler","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0015-0282(03)00735-0","article-title":"Androgen excess is the key element in polycystic ovary syndrome.","volume":"80","author":"Azziz","year":"2003","journal-title":"Fertil Steril"},{"key":"2020071615453605400_R9","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.286.19.2421","article-title":"Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.","volume":"286","author":"Solomon","year":"2001","journal-title":"JAMA"},{"key":"2020071615453605400_R10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00060793-200212000-00003","article-title":"Diabetes prevalence and risk factors in polycystic ovary syndrome.","volume":"9","author":"Legro","year":"2002","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"2020071615453605400_R11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9343(01)00948-2","article-title":"Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.","volume":"111","author":"Legro","year":"2001","journal-title":"Am J Med"},{"key":"2020071615453605400_R12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2796.1996.364690000.x","article-title":"The android woman\u2013a risky condition.","volume":"239","author":"Bjorntorp","year":"1996","journal-title":"J Intern Med"},{"key":"2020071615453605400_R13","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/01.CIR.103.10.1410","article-title":"Polycystic ovary syndrome is associated with endothelial dysfunction.","volume":"103","author":"Paradisi","year":"2001","journal-title":"Circulation"},{"key":"2020071615453605400_R14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1210\/er.2003-0004","article-title":"Polycystic ovary syndrome and cardiovascular disease: a premature association?","volume":"24","author":"Legro","year":"2003","journal-title":"Endocr Rev"},{"key":"2020071615453605400_R15","first-page":"CD003053","article-title":"Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome","volume":"3","author":"Lord","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2020071615453605400_R16","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1210\/jcem.87.6.8568","article-title":"Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.","volume":"87","author":"Iban\u0303ez","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R17","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(03)13493-9","article-title":"Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome.","volume":"361","author":"Harborne","year":"2003","journal-title":"Lancet"},{"key":"2020071615453605400_R18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0015-0282(02)04800-8","article-title":"Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome.","volume":"79","author":"Haas","year":"2003","journal-title":"Fertil Steril"},{"key":"2020071615453605400_R19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"2020071615453605400_R20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","article-title":"Metformin in polycystic ovary syndrome: systematic review and meta-analysis.","volume":"327","author":"Lord","year":"2003","journal-title":"BMJ"},{"key":"2020071615453605400_R21","first-page":"2108","article-title":"Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.","volume":"82","author":"Ehrmann","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R22","first-page":"3299","article-title":"The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.","volume":"81","author":"Dunaif","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R23","first-page":"524","article-title":"Effect of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in woman with polycystic ovary syndrome.","volume":"82","author":"Ehrmann","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R24","first-page":"1626","article-title":"Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.","volume":"86","author":"Azziz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R25","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/humrep\/deg343","article-title":"Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.","volume":"18","author":"Glueck","year":"2003","journal-title":"Hum Reprod"},{"key":"2020071615453605400_R26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/humrep\/deg264","article-title":"Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.","volume":"18","author":"Romualdi","year":"2003","journal-title":"Hum Reprod"},{"key":"2020071615453605400_R27","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1210\/jc.2003-031737","article-title":"Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism and ovulatory dysfunction in women with polycystic ovary syndrome.","volume":"89","author":"Brettenthaler","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R28","first-page":"363","article-title":"Fasting glucose\/insulin ratio. An index to differentiate normo- from hyperinsulinemic women with polycystic ovary syndrome.","volume":"46","author":"Parra","year":"1994","journal-title":"Rev Invest Clin"},{"key":"2020071615453605400_R29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","article-title":"Clinical assessment of body hair growth in women.","volume":"21","author":"Ferriman","year":"1961","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s001250051561","article-title":"Assessment of insulin sensitivity and \u03b2-cell function from measurements in the fasting state and during and oral glucose tolerance test.","volume":"43","author":"Albareda","year":"2000","journal-title":"Diabetologia"},{"key":"2020071615453605400_R31","first-page":"4426","article-title":"Insulin sensitivity and its measurement: structural commonalities among the methods.","volume":"85","author":"Radziuk","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R32","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.","volume":"85","author":"Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2337\/diacare.17.2.152","article-title":"A mathematical model for the determination of total area under glucose tolerance and other metabolic curves.","volume":"17","author":"Tai","year":"1994","journal-title":"Diabetes Care"},{"key":"2020071615453605400_R34","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1210\/jc.2003-030424","article-title":"Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.","volume":"88","author":"Harborne","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R35","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2002-021786","article-title":"Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.","volume":"88","author":"Pavo","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/humrep\/16.5.940","article-title":"Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?","volume":"16","author":"Cibula","year":"2001","journal-title":"Hum Reprod"},{"key":"2020071615453605400_R37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2337\/diacare.22.2.288","article-title":"Effects of a thiazolidinedione compound on body fat distribution of patients with type 2 diabetes.","volume":"22","author":"Kelly","year":"1999","journal-title":"Diabetes Care"},{"key":"2020071615453605400_R38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/diacare.23.8.1067","article-title":"Efficacy of troglitazone on body fat distribution in type 2 diabetes.","volume":"23","author":"Akazawa","year":"2000","journal-title":"Diabetes Care"},{"issue":"Suppl 8A","key":"2020071615453605400_R39","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1016\/j.amjmed.2003.09.005","article-title":"Effect of thiazolidinediones on body weight in patients with diabetes mellitus","volume":"115","author":"Fonseca","year":"2003","journal-title":"Am J Med"},{"key":"2020071615453605400_R40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1095\/biolreprod66.1.190","article-title":"Putative activation of the peroxisome proliferator activated receptor \u03b3 impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells.","volume":"66","author":"Schoppee","year":"2002","journal-title":"Biol Reprod"},{"key":"2020071615453605400_R41","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1210\/jcem.87.3.8308","article-title":"Troglitazone, an insulin sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by theca cells in vitro.","volume":"87","author":"Veldhuis","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R42","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1210\/jcem.87.4.8404","article-title":"The biological variation of insulin resistance in polycystic ovarian syndrome.","volume":"87","author":"Jayagopal","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615453605400_R43","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0015-0282(01)02843-6","article-title":"Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.","volume":"76","author":"Cataldo","year":"2001","journal-title":"Fertil Steril"},{"key":"2020071615453605400_R44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0015-0282(02)04843-4","article-title":"Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.","volume":"79","author":"Ghazeeri","year":"2003","journal-title":"Fertil Steril"},{"key":"2020071615453605400_R45","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/humrep\/17.11.2858","article-title":"Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.","volume":"17","author":"Glueck","year":"2002","journal-title":"Hum Reprod"},{"key":"2020071615453605400_R46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/jcem.87.2.8207","article-title":"Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.","volume":"87","author":"Jakubowicz","year":"2002","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/3\/1360\/10743877\/jcem1360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/3\/1360\/10743877\/jcem1360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:53:51Z","timestamp":1594954431000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/90\/3\/1360\/2836677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,1]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2004-1965","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,1]]}}}